- ￥1668
- abinScience
- China
- VK018013
- 2026年03月03日
- ELISA, Neutralization, BLI
- Human
- Sin Nombre Virus
企业认证
相关产品推荐更多 >
Anti-CSTA Polyclonal Antibody, 抗CSTA多克隆抗体
￥1008
Anti-Human CD143/ACE Antibody (SAA2704), 抗人CD143/ACE抗体 (SAA2704)
询价
Anti-ENO2/NSE Polyclonal Antibody, 抗ENO2/NSE多克隆抗体
￥1008Anti-Mouse CDw210b/IL10RB Antibody (SAA2105), PerCP, 抗小鼠CDw210b/IL10RB抗体 (SAA2105), PerCP标记
询价Feline IgG2, kappa Isotype Control antibody (HyHEL-10), FITC, 同型对照抗体
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Human
- 亚型：
IgG1, lambda
- 形态：
Liquid
- 保存条件：
0.01M PBS, pH 7.4.
- 克隆性：
Monoclonal
- 标记物：
Unconjugated
- 适应物种：
Sin Nombre Virus
- 保质期：
1 year
- 抗原来源：
Human
- 目录编号：
VK018013
- 级别：
科研级别
- 库存：
999
- 供应商：
abinScience
- 宿主：
Human
- 应用范围：
ELISA, Neutralization, BLI
- 浓度：
1mg/mL
- 靶点：
Envelopment polyprotein, Glycoprotein N, Gn, Glycoprotein G1, GP
- 抗体英文名：
Anti-SNV Glycoprotein Gn Antibody (SNV-42)
- 抗体名：
Anti-SNV Glycoprotein Gn Antibody (SNV-42)
- 规格：
100ul
| Product name | Anti-SNV Glycoprotein Gn Antibody (SNV-42) |
|---|---|
| Catalog No. | VK018013 |
| Host species | Human |
| Species reactivity | Sin Nombre Virus |
| Immunogen | / |
| Form | Liquid |
| Storage buffer | 0.01M PBS, pH 7.4. |
| Purity | >90% as determined by SDS-PAGE. |
| Clonality | Monoclonal |
| Isotype | IgG1, lambda |
| Applications | ELISA, Neutralization, BLI |
| Target | Envelopment polyprotein, Glycoprotein N, Gn, Glycoprotein G1, GP |
| Purification | Protein A/G purified from cell culture supernatant. |
| Endotoxin level | Please contact with the lab for this information. |
| Expression system | / |
| Accession | Q89905 |
| Alternative Names | / |
| Clone ID | SNV-42 |
| Species | / |
| Product Usage Information | / |
abinScience, founded in 2023 in Strasbourg, France, is committed to developing and producing high-quality life science reagents. Rooted in one of Europe’s leading hubs for scientific innovation, abinScience empowers global research through reliable, efficient experimental solutions. Guided by the vision of “Empowering Bioscience Discovery,” we support scientists worldwide in advancing the frontiers of bioscience.
Technology and Innovation
Relying on the global leading position in antibody and protein research and more than 20 years of industry experience of its parent company ProteoGenix since 2003, abinScience has inherited advanced technologies and high-quality standards. In particular, the XtenCHO™ system developed by ProteoGenix, which has two modes of transient expression and stable expression, has been widely recognized as a core technology to improve the efficiency of protein production, providing a solid foundation for abinScience's product research and development.
Product categories and application fields.
Main products.
10000+ high-activity proteins.
15000+ antibody series products:
Classic monoclonal antibody.
Monoclonal antibody
Internal control antibody, labeled antibody.
High-quality phosphorylation antibodies.
Highly specific nanobodies and small molecule antibodies.
Functional antibodies in vivo.
Low-background flow cytometry antibodies.
DNA/RNA antibodies and PEG antibodies.
1000+ reagent kit series products.
Large-scale packaging customization services: We offer personalized antibody design, protein production, molecular optimization, and experimental development services.
Application field
Infectious disease research: including viruses, superbugs, parasites, etc.
Neuroscience research: Supporting research on neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
Immunology research: Covers the research needs of immune activation, inhibition, and allergies and abnormal reactions.
Oncology research: Supporting the development of tumor biology and anti-tumor drugs.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验-phosphoserine的抗体。 摘抄： Anti-Phosphothreonine (MAb) - CryptateThe anti-phosphothreonine antibody is a monoclonal antibody (clone 42H4) produced at Cell Signaling Technology (reference 9386). It recognizes phosphorylated threonine residues in a manner
Nature 综述导读：FDA 批准第 100 个抗体药物！抗体药物的研究方向在哪里？
批准了第 50 种抗体，距离第一个抗体已经过去了 29 年。2021 年 4 月，随着葛兰素史克 PD1 阻断剂 dostarlimab 的批准，抗体药物仅用了 6 年多的时间就达到了 100 个，进入了「百抗」新时代（图五）。 图五 Nature Reviews Drug Discovery 20, 10 (2021) 上面提到的 100 个抗体并不是单纯经典的单克隆的裸抗体（naked antibody），其中也包括了抗体片段已经工程化修饰抗体的各种偶联形式。其中包括有抗体药物偶联（ADC
类细胞为效应细胞来构建双特异抗体更为常见：第一.T细胞群中存在着免疫记忆细胞；第二.有证据表明在恶性肿瘤患者体内存在着肿瘤特异性的T细胞；第三.体内外实验表明抗CD3抗体激活的杀伤细胞（CD3AK）比IL-2激活的杀伤细胞（LAK）具有更强大的细胞毒效应[2]。体内外生物学实验结果表明：Diabody能同时与T细胞和癌细胞结合，并通过激活T细胞，来靶向杀灭癌细胞[3，4]。HIT3a[5]和PHMA02[6]是我所研制的鼠源性抗CD3和抗Pgp（P-glycoprotein）单克隆抗体，我们在克隆单克隆抗体
技术资料暂无技术资料 索取技术资料
